Dataset Information

Amyloid Beta Peptide (A?1-42) Reverses the Cholinergic Control of Monocytic IL-1? Release.

ABSTRACT: Amyloid-? peptide (A?1-42), the cleavage product of the evolutionary highly conserved amyloid precursor protein, presumably plays a pathogenic role in Alzheimer's disease. A?1-42 can induce the secretion of the pro-inflammatory cytokine intereukin-1? (IL-1?) in immune cells within and out of the nervous system. Known interaction partners of A?1-42 are ?7 nicotinic acetylcholine receptors (nAChRs). The physiological functions of A?1-42 are, however, not fully understood. Recently, we identified a cholinergic mechanism that controls monocytic release of IL-1? by canonical and non-canonical agonists of nAChRs containing subunits ?7, ?9, and/or ?10. Here, we tested the hypothesis that A?1-42 modulates this inhibitory cholinergic mechanism. Lipopolysaccharide-primed monocytic U937 cells and human mononuclear leukocytes were stimulated with the P2X7 receptor agonist 2'(3')-O-(4-benzoylbenzoyl)adenosine-5'-triphosphate triethylammonium salt (BzATP) in the presence or absence of nAChR agonists and A?1-42. IL-1? concentrations were measured in the supernatant. A?1-42 dose-dependently (IC50 = 2.54 µM) reversed the inhibitory effect of canonical and non-canonical nicotinic agonists on BzATP-mediated IL-1?-release by monocytic cells, whereas reverse A?42-1 was ineffective. In conclusion, we discovered a novel pro-inflammatory A?1-42 function that enables monocytic IL-1? release in the presence of nAChR agonists. These findings provide evidence for a novel physiological function of A?1-42 in the context of sterile systemic inflammation.

SUBMITTER: Richter K

PROVIDER: S-EPMC7564705 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Amyloid Beta Peptide (Aβ1-42) Reverses the Cholinergic Control of Monocytic IL-1β Release.

Richter Katrin K Ogiemwonyi-Schaefer Raymond R Wilker Sigrid S Chaveiro Anna I AI Agné Alisa A Hecker Matthias M Reichert Martin M Amati Anca-Laura AL Schlüter Klaus-Dieter KD Manzini Ivan I Schmalzing Günther G McIntosh J Michael JM Padberg Winfried W Grau Veronika V Hecker Andreas A

Journal of clinical medicine 20200907 9

Amyloid-β peptide (Aβ1-42), the cleavage product of the evolutionary highly conserved amyloid precursor protein, presumably plays a pathogenic role in Alzheimer's disease. Aβ1-42 can induce the secretion of the pro-inflammatory cytokine intereukin-1β (IL-1β) in immune cells within and out of the nervous system. Known interaction partners of Aβ1-42 are α7 nicotinic acetylcholine receptors (nAChRs). The physiological functions of Aβ1-42 are, however, not ...[more]

PMID: 32906646

Similar Datasets

Project description:Aims/hypothesisAggregation of the beta cell secretory product human islet amyloid polypeptide (hIAPP) results in islet amyloid deposition, a pathological feature of type 2 diabetes. Amyloid formation is associated with increased levels of islet IL-1β as well as beta cell dysfunction and death, but the mechanisms that promote amyloid deposition in situ remain unclear. We hypothesised that physiologically relevant concentrations of IL-1β stimulate beta cell islet amyloid polypeptide (IAPP) release and promote amyloid formation.MethodsWe used a humanised mouse model of endogenous beta cell hIAPP expression to examine whether low (pg/ml) concentrations of IL-1β promote islet amyloid formation in vitro. Amyloid-forming islets were cultured for 48 h in the presence or absence of IL-1β with or without an IL-1β neutralising antibody. Islet morphology was assessed by immunohistochemistry and islet mRNA expression, hormone content and release were also quantified. Cell-free thioflavin T assays were used to monitor hIAPP aggregation kinetics in the presence and absence of IL-1β.ResultsTreatment with a low concentration of IL-1β (4 pg/ml) for 48 h increased islet amyloid prevalence (93.52 ± 3.89% vs 43.83 ± 9.67% amyloid-containing islets) and amyloid severity (4.45 ± 0.82% vs 2.16 ± 0.50% amyloid area/islet area) in hIAPP-expressing mouse islets in vitro. This effect of IL-1β was reduced when hIAPP-expressing islets were co-treated with an IL-1β neutralising antibody. Cell-free hIAPP aggregation assays showed no effect of IL-1β on hIAPP aggregation in vitro. Low concentration IL-1β did not increase markers of the unfolded protein response (Atf4, Ddit3) or alter proIAPP processing enzyme gene expression (Pcsk1, Pcsk2, Cpe) in hIAPP-expressing islets. However, release of IAPP and insulin were increased over 48 h in IL-1β-treated vs control islets (IAPP 0.409 ± 0.082 vs 0.165 ± 0.051 pmol/5 islets; insulin 87.5 ± 8.81 vs 48.3 ± 17.3 pmol/5 islets), and this effect was blocked by co-treatment with IL-1β neutralising antibody.Conclusions/interpretationUnder amyloidogenic conditions, physiologically relevant levels of IL-1β promote islet amyloid formation by increasing beta cell release of IAPP. Neutralisation of this effect of IL-1β may decrease the deleterious effects of islet amyloid formation on beta cell function and survival.

Dataset Information

Amyloid Beta Peptide (A?1-42) Reverses the Cholinergic Control of Monocytic IL-1? Release.

Publications

Amyloid Beta Peptide (Aβ<sub>1-42</sub>) Reverses the Cholinergic Control of Monocytic IL-1β Release.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets